The purpose of this guidance is to identify the types of decision support software functionalities that: (1) do not meet the definition of a device as amended by the Cures Act; (2) may meet the definition of a device but for which FDA does not intend to enforce compliance with applicable requirements of the FD&C Act, including, but not limited to, premarket clearance and premarket approval requirements; and (3) FDA intends to focus its regulatory oversight on.
News & Trends
Procurar
Recentes
- Risk based approach to Post Market Clinical Follow up (PMCF)
- Questions & Answers on the impact of Mutual Recognition Agreement (MRA) between the European Union and the United States
- Digital label for authorised representative and importer
- MANUAL PARA REGULARIZAÇÃO DE EQUIPAMENTO MÉDICO E SOFTWARE COMO DISPOSITIVO MÉDICO NA ANVISA
- How to Prepare a PreRequest for Designation (Pre-RFD) . FDA Guidance for Industry
- Formação exclusiva Formiventos CTD MODULO 3: “Evento de alta qualidade que permitiu grande interação entre todos os participantes. “
- PREÇOS 2025: “Muito interessante e enriquecedora”
- GUIDANCE DOCUMENT Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications